Stock profile
NANOBIOTIX
NANO.PA · FR0011341205 · Euronext Paris
Healthcare · Biotechnology
SBF 120
Latest daily close
27.00 EUR
-1.03%
Data as of 6 November 2026 · Volume 107,831
3-month Momentum · SBF 120
56.58
Rank #43 / 120
Solidity
26.08
15 sector-relative components
Market regime · SBF 120
Pending
Shown after production-rule validation
Performance
Total returns calculated from adjusted daily closing prices.
1 day-1.03%
1 week-3.98%
1 month+27.12%
3 months-18.63%
6 months-19.45%
YTD+38.46%
1 year+39.46%
3 years+385.61%
5 years+197.52%
Full history+335.48%
Momentum rankings
Scores are relative to each universe. M0, M-1 and M-2 each carry 33.33%; volatility has a 0% score weight.
| Period | Universe | Rank | Total score | M0 perf. / score | M-1 perf. / score | M-2 perf. / score | Annualized vol. | Data date |
|---|---|---|---|---|---|---|---|---|
| 1 Month | SBF 120 | #98 / 120 | 35.85 | -11.07% / 5.04 | +61.06% / 100.00 | -7.23% / 2.52 | 83.70% | 6 November 2026 |
| 3 Months | SBF 120 | #43 / 120 | 56.58 | +19.79% / 94.96 | -32.56% / 0.00 | +0.66% / 74.79 | 99.02% | 6 November 2026 |
| 6 Months | SBF 120 | #103 / 120 | 32.77 | -19.21% / 10.92 | -5.00% / 35.29 | +1.38% / 52.10 | 84.54% | 6 November 2026 |
| 1 Year | SBF 120 | #19 / 120 | 63.31 | -23.25% / 10.08 | +22.79% / 82.35 | +63.34% / 97.48 | 77.51% | 6 November 2026 |
Technical analysis
One year of adjusted prices with moving averages and daily volume.
Adjusted priceSMA 20SMA 50SMA 200Volume bars
SMA 2024.71
SMA 5027.34
SMA 20029.40
RSI 1452.88
MACD0.403
MACD signal0.012
MACD histogram0.391
ATR 147.82%
Fundamental solidity
Five weighted pillars built from 15 sector-relative percentile indicators.
Valuation · 0%—
Profitability · 40%16.17
Balance sheet · 27%50.00
Growth · 0%—
Cash flow · 33%18.82
| Pillar | Indicator | Value | Score | Comparison |
|---|---|---|---|---|
| Valuation | Trailing P/E | — | — | — |
| Valuation | Forward P/E | — | — | — |
| Valuation | EV / EBITDA | — | — | — |
| Profitability | Profit margin | -73.52% | 11.76 | Sector · Healthcare |
| Profitability | Operating margin | -196.42% | 11.76 | Sector · Healthcare |
| Profitability | Return on assets | -10.06% | 23.53 | Sector · Healthcare |
| Profitability | Return on equity | — | — | — |
| Balance Sheet | Debt / equity | — | — | — |
| Balance Sheet | Net debt / EBITDA | — | — | — |
| Balance Sheet | Current ratio | 1.09x | 35.29 | Sector · Healthcare |
| Balance Sheet | Quick ratio | 1.05x | 64.71 | Sector · Healthcare |
| Growth | Revenue growth | — | — | — |
| Growth | Earnings growth | — | — | — |
| Cashflow | Free cash flow margin | -24.22% | 23.53 | Sector · Healthcare |
| Cashflow | Operating cash flow margin | -102.54% | 11.76 | Sector · Healthcare |
Risk and market behaviour
Risk
- Volatility · 21 sessions
- 96.93%
- Volatility · 60 sessions
- 87.01%
- Volatility · 252 sessions
- 74.74%
- Maximum drawdown · 1 year
- -59.18%
- Maximum drawdown · 5 years
- -81.25%
- Current drawdown from ATH
- -41.53%
- Distance from 52-week high
- -43.35%
- 52-week range position
- 33.65%
Trading sessions · 1 year
- Positive sessions
- 48.02%
- Average positive session
- +3.85%
- Average negative session
- -3.14%
- Best session
- +19.24%
- Worst session
- -11.72%
- Longest rising streak
- 7 sessions
- Longest falling streak
- 7 sessions
- Average monthly return
- +4.93%
Fundamentals and dividends
Key fundamentals
- Market capitalization
- 1,880,019,728
- Enterprise value
- 1,910,343,808
- Trailing P/E
- —
- Forward P/E
- -155.79
- EV / EBITDA
- -182.13
- Profit margin
- -73.52%
- Operating margin
- -196.42%
- Revenue growth
- —
- Net debt
- 42,569,000
Dividends and consensus
- Last dividend date
- —
- Last dividend per share
- —
- Trailing 12-month dividend
- 0.00 EUR
- Trailing dividend yield
- 0.00%
- Analyst target mean
- 52.20 EUR
- Analyst count
- 5
Market regime: the SBF 120 field remains intentionally pending until the production trend rule is validated. No investment signal is inferred.
MarketMoveForecast rankings, statistics and indicators are provided for information and educational purposes only. They do not constitute investment advice. Market data may contain delays, omissions or errors, and past performance does not guarantee future results.